Compare GSK plc (GSK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares UltraPro S&P500 — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while ProShares UltraPro S&P500 trades at $154.44. The key difference: GSK plc pays a 3.57% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | UPRO | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $155.10 |
52-Week Low | $38.22 | $89.29 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
UPRO trades at $154.55, down 0.28% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF shows strong institutional interest with Bay Colony Advisors establishing a new position. Market sentiment is mixed as the S&P 500 faces valuation concerns at record highs, with the Fear & Greed index indicating greed zone conditions amid inflation data anticipation.
The leveraged ETF's performance remains tied to S&P 500 momentum, with technical support at $150-$152 providing downside protection. Key risks include market volatility and overbought conditions, while institutional accumulation suggests confidence in near-term upside potential despite broader market valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
